Posted On:
18 OCT 2026 4:30PM by PIB Guwahati
AIIMS Guwahati has welcomed the Government of India’s initiative to reduce the prices of 137 identified non-scheduled anti-cancer medicines through Trade Margin Rationalisation (TMR), aimed at making cancer treatment more affordable for patients and their families.
The initiative has been undertaken by the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. The maximum retail prices (MRPs) of the identified medicines will be reduced by up to 70 per cent with effect from 9 November 2026.
The measure seeks to rationalise trade margins on selected anti-cancer medicines and reduce the financial burden associated with cancer treatment.
The medicines covered under the initiative include pembrolizumab and durvalumab, which are used in cancer immunotherapy; osimertinib, used in the treatment of certain types of lung cancer; bevacizumab, used for various types of cancer; denosumab, used in selected cases of breast and prostate cancer; and pegfilgrastim, which helps reduce the risk of infection caused by low white blood cell counts during cancer treatment.
Prof. (Dr.) Ashok Puranik, Executive Director, AIIMS Guwahati, said that the reduction in prices of anti-cancer medicines would help reduce the financial burden on patients requiring these medicines. He also emphasised the importance of awareness about the revised prices so that eligible patients can benefit from the initiative.
Patients and caregivers can check the revised prices through hospital pharmacies, the NPPA website and the Pharma Sahi Daam application. Patients are advised to consult their treating oncologists before making any changes to their prescribed medicines or treatment.
…………….
PG/ SM